These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18718922)

  • 1. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
    Roquebert B; Damond F; Collin G; Matheron S; Peytavin G; Bénard A; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
    J Antimicrob Chemother; 2008 Nov; 62(5):914-20. PubMed ID: 18718922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir.
    Bercoff DP; Triqueneaux P; Lambert C; Oumar AA; Ternes AM; Dao S; Goubau P; Schmit JC; Ruelle J
    Retrovirology; 2010 Nov; 7():98. PubMed ID: 21114823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
    Nguyen HL; Ruxrungtham K; Delaugerre C
    Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.
    Van Baelen K; Van Eygen V; Rondelez E; Stuyver LJ
    AIDS; 2008 Sep; 22(14):1877-80. PubMed ID: 18753927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
    da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
    J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.
    Alessandri-Gradt E; Collin G; Tourneroche A; Bertine M; Leoz M; Charpentier C; Unal G; Descamps D; Plantier JC
    J Antimicrob Chemother; 2017 Sep; 72(9):2431-2437. PubMed ID: 28859447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.
    Charpentier C; Bertine M; Visseaux B; Leleu J; Larrouy L; Peytavin G; Mourez T; Collin G; Brun-Vézinet F; Plantier JC; Descamps D
    AIDS; 2013 Nov; 27(18):2959-61. PubMed ID: 23942060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
    Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
    Ni XJ; Delelis O; Charpentier C; Storto A; Collin G; Damond F; Descamps D; Mouscadet JF
    Retrovirology; 2011 Aug; 8():68. PubMed ID: 21854605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
    Margot NA; Hluhanich RM; Jones GS; Andreatta KN; Tsiang M; McColl DJ; White KL; Miller MD
    Antiviral Res; 2012 Feb; 93(2):288-296. PubMed ID: 22197635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
    Marinello J; Marchand C; Mott BT; Bain A; Thomas CJ; Pommier Y
    Biochemistry; 2008 Sep; 47(36):9345-54. PubMed ID: 18702518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.
    Hightower KE; Wang R; Deanda F; Johns BA; Weaver K; Shen Y; Tomberlin GH; Carter HL; Broderick T; Sigethy S; Seki T; Kobayashi M; Underwood MR
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4552-9. PubMed ID: 21807982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
    Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N
    J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
    Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.
    Huang W; Frantzell A; Fransen S; Petropoulos CJ
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4105-13. PubMed ID: 23733474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 integrase inhibitor resistance and its clinical implications.
    Blanco JL; Varghese V; Rhee SY; Gatell JM; Shafer RW
    J Infect Dis; 2011 May; 203(9):1204-14. PubMed ID: 21459813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.
    Malet I; Gimferrer Arriaga L; Artese A; Costa G; Parrotta L; Alcaro S; Delelis O; Tmeizeh A; Katlama C; Valantin MA; Ceccherini-Silberstein F; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2014 Aug; 69(8):2118-22. PubMed ID: 24710029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
    Salgado M; Toro C; Simón A; Garrido C; Blanco F; Soriano V; Rodés B
    J Clin Virol; 2009 Oct; 46(2):173-5. PubMed ID: 19625211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural polymorphisms of integrase among HIV type 1-infected South African patients.
    Fish MQ; Hewer R; Wallis CL; Venter WD; Stevens WS; Papathanasopoulos MA
    AIDS Res Hum Retroviruses; 2010 Apr; 26(4):489-93. PubMed ID: 20377427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.